Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Neutralizing Antibody Therapeutics for COVID-19
Aeron C. Hurt, Adam K. Wheatley
Viruses (2021) Vol. 13, Iss. 4, pp. 628-628
Open Access | Times Cited: 119

Showing 1-25 of 119 citing articles:

Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients
Angélica Jayk Bernal, Monica Maria Gomes da Silva, Dany Badibanga Musungaie, et al.
New England Journal of Medicine (2021) Vol. 386, Iss. 6, pp. 509-520
Open Access | Times Cited: 1673
Seroconversion rates following COVID-19 vaccination among patients with cancer
Astha Thakkar, Jesus D. Gonzalez‐Lugo, Niyati Goradia, et al.
Cancer Cell (2021) Vol. 39, Iss. 8, pp. 1081-1090.e2
Open Access | Times Cited: 341
The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies
Chiranjib Chakraborty, Ashish Ranjan Sharma, Manojit Bhattacharya, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 140
Alpha to Omicron: Disease Severity and Clinical Outcomes of Major SARS-CoV-2 Variants
Frank Esper, Thamali M. Adhikari, Zheng Jin Tu, et al.
The Journal of Infectious Diseases (2022) Vol. 227, Iss. 3, pp. 344-352
Open Access | Times Cited: 120
Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Pan-Pan Zhou, Ge Song, Hejun Liu, et al.
Immunity (2023) Vol. 56, Iss. 3, pp. 669-686.e7
Open Access | Times Cited: 120
The Emergence of Omicron: Challenging Times Are Here Again!
Tanu Singhal
The Indian Journal of Pediatrics (2022) Vol. 89, Iss. 5, pp. 490-496
Open Access | Times Cited: 101
An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19
Awadhesh Kumar Singh, Akriti Singh, Ritu Singh, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2022) Vol. 16, Iss. 2, pp. 102396-102396
Open Access | Times Cited: 89
Conformational dynamics and allosteric modulation of the SARS-CoV-2 spike
Marco A. Díaz-Salinas, Qi Li, Monir Ejemel, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 74
Broadly-Neutralizing Antibodies Against Emerging SARS-CoV-2 Variants
Lok Bahadur Shrestha, Nicodemus Tedla, Rowena A. Bull
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 79
Therapeutics for COVID-19 and post COVID-19 complications: An update
Debdoot Basu, Vivek P. Chavda, Anita A. Mehta
Current Research in Pharmacology and Drug Discovery (2022) Vol. 3, pp. 100086-100086
Open Access | Times Cited: 69
Household Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 in the United States: Living Density, Viral Load, and Disproportionate Impact on Communities of Color
Anthony Cerami, Zachary R. Popkin-Hall, Tyler Rapp, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 10, pp. 1776-1785
Open Access | Times Cited: 65
A systematic review of Vaccine Breakthrough Infections by SARS-CoV-2 Delta Variant
Mengxin Zhang, Ying Liang, Dongsheng Yu, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 2, pp. 889-900
Open Access | Times Cited: 61
COVID-19 in B Cell-Depleted Patients After Rituximab: A Diagnostic and Therapeutic Challenge
Anna Furlan, Gabriella Forner, Ludovica Cipriani, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 57
The impact of neutralizing monoclonal antibodies on the outcomes of COVID‐19 outpatients: A systematic review and meta‐analysis of randomized controlled trials
Wei‐Ting Lin, Shun‐Hsing Hung, Chih‐Cheng Lai, et al.
Journal of Medical Virology (2022) Vol. 94, Iss. 5, pp. 2222-2229
Open Access | Times Cited: 56
Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses
Wanting He, Rami Musharrafieh, Ge Song, et al.
Nature Immunology (2022) Vol. 23, Iss. 6, pp. 960-970
Open Access | Times Cited: 56
Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters
Yong‐Qiang Deng, Nana Zhang, Yifei Zhang, et al.
Cell Research (2022) Vol. 32, Iss. 4, pp. 375-382
Open Access | Times Cited: 42
A neutralizing epitope on the SD1 domain of SARS-CoV-2 spike targeted following infection and vaccination
Jeffrey Seow, Hataf Khan, Annachiara Rosa, et al.
Cell Reports (2022) Vol. 40, Iss. 8, pp. 111276-111276
Open Access | Times Cited: 41
Efficacy and safety of SIM0417 (SSD8432) plus ritonavir for COVID-19 treatment: a randomised, double-blind, placebo-controlled, phase 1b trial
Fuxiang Wang, Wen Xiao, Yimin Tang, et al.
The Lancet Regional Health - Western Pacific (2023) Vol. 38, pp. 100835-100835
Open Access | Times Cited: 27
Broadly neutralizing antibodies isolated from HEV convalescents confer protective effects in human liver-chimeric mice
George Ssebyatika, Katja Dinkelborg, L.J. Stroh, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access | Times Cited: 1
SARS‐CoV‐2 variants preferentially emerge at intrinsically disordered protein sites helping immune evasion
Federica Quaglia, Edoardo Salladini, Marco Carraro, et al.
FEBS Journal (2022) Vol. 289, Iss. 14, pp. 4240-4250
Open Access | Times Cited: 32
Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression
Shuai Yang, Yun Ling, Fang Zhao, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 30
Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development
Xuemei He, Cai He, Weiqi Hong, et al.
Medicinal Research Reviews (2023) Vol. 43, Iss. 4, pp. 932-971
Open Access | Times Cited: 17
Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial
May Ee Png, Victoria Harris, Jenna Grabey, et al.
British Journal of General Practice (2024) Vol. 74, Iss. 745, pp. e570-e579
Open Access | Times Cited: 8
E484K and N501Y SARS-CoV 2 spike mutants Increase ACE2 recognition but reduce affinity for neutralizing antibody
Sandipan Chakraborty
International Immunopharmacology (2021) Vol. 102, pp. 108424-108424
Open Access | Times Cited: 41
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
Heinz Ludwig, Pieter Sonneveld, Thierry Façon, et al.
The Lancet Haematology (2021) Vol. 8, Iss. 12, pp. e934-e946
Open Access | Times Cited: 33
Page 1 - Next Page

Scroll to top